Genotypic and phenotypic features of de novo and acquired resistance to cancer therapies.

被引：0
|
作者：
Dancey, Janet E. [1 ]
机构：
[1] Ontario Inst Canc Res, Toronto, ON, Canada
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-SY03-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
SY0301
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Genotypic and phenotypic comparisons of de Novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model
    Hazlehurst, LA
    Enkemann, SA
    Beam, CA
    Argilagos, RF
    Painter, J
    Shain, KH
    Saporta, S
    Boulware, D
    Moscinski, L
    Alsina, M
    Dalton, WS
    CANCER RESEARCH, 2003, 63 (22) : 7900 - 7906
  • [2] Mechanisms of acquired resistance to targeted cancer therapies
    Lackner, Mark R.
    Wilson, Timothy R.
    Settleman, Jeff
    FUTURE ONCOLOGY, 2012, 8 (08) : 999 - 1014
  • [3] De-novo and acquired resistance to immune checkpoint targeting
    Syn, Nicholas L.
    Teng, Michele W. L.
    Mok, Tony S. K.
    Soo, Ross A.
    LANCET ONCOLOGY, 2017, 18 (12): : E731 - E741
  • [4] PHENOTYPIC FEATURES OF PATIENTS WITH SCHIZOPHRENIA CARRYING DE NOVO GENE MUTATIONS
    Malherbe, Pierre J.
    Roos, J. Louis
    Roos, J. Louw
    Karayiorgou, Maria
    Ehlers, Rene
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S344 - S344
  • [5] Phenotypic features of patients with schizophrenia carrying de novo gene mutations
    Malherbe, P. J.
    Roos , J. L.
    Ehlers, R.
    Karayiorgou, M.
    Roos, J. L.
    SOUTH AFRICAN JOURNAL OF PSYCHIATRY, 2014, 20 (03) : 122 - 122
  • [6] Cancer Cells with De Novo or Acquired Resistance to Carfilzomib Remain Dependent on the Proteasome for Their Survival and Growth
    Lee, Min Jae
    Driscoll, James
    Kim, Kyung Bo
    FASEB JOURNAL, 2017, 31
  • [7] De novo neuroendocrine features in prostate cancer
    Abdulfatah, Eman
    Fine, Samson W.
    Lotan, Tamara L.
    Mehra, Rohit
    HUMAN PATHOLOGY, 2022, 127 : 112 - 122
  • [8] Evolution of Acquired Resistance to Targeted Therapies in Lung Cancer
    Hata, Aaron N.
    ONCOLOGIST, 2014, 19 : S4 - S4
  • [9] Acquired Resistance to Crizotinib in Advanced NSCLC with De Novo MET Overexpression
    Li, A.
    Yang, J.
    Zhang, X.
    Su, J.
    Zhou, Q.
    Chen, H.
    Xie, Z.
    Tu, H.
    Zhong, W.
    Wang, Z.
    Xu, C.
    Chen, Z.
    Yan, H.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1899 - S1899
  • [10] Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma
    Zhao, Xiaohong
    Lwin, Tint
    Silva, Ariosto
    Shah, Bijal
    Tao, Jiangchuan
    Fang, Bin
    Zhang, Liang
    Fu, Kai
    Bi, Chengfeng
    Li, Jiannong
    Jiang, Huijuan
    Meads, Mark B.
    Jacobson, Timothy
    Silva, Maria
    Distler, Allison
    Darville, Lancia
    Zhang, Ling
    Han, Ying
    Rebatchouk, Dmitri
    Di Liberto, Maurizio
    Moscinski, Lynn C.
    Koomen, John M.
    Dalton, William S.
    Shain, Kenneth H.
    Wang, Michael
    Sotomayor, Eduardo
    Tao, Jianguo
    NATURE COMMUNICATIONS, 2017, 8
12345